Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Live Attenuated Tetravalent Dengue Vaccine KD-382 in Healthy Adults and Children
TCTR20241231011Phase 2Recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Jul 2025
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of KD-382 in dengue fever, sponsored by Meiji Seika Pharma Co., Ltd.. Started Jul 2025; status: recruiting.
02
Drugs
KD-382
03
Conditions
dengue fever
Beyond the preview
Go deeper on TCTR20241231011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241231011.